Resources Repository
-
OrganizationWeb Portal 2024Society for Medical Decision Making
The Society for Medical Decision Making (SMDM), founded in 1979, works to improve health and …
The Society for Medical Decision Making (SMDM), founded in 1979, works to improve health and clinical care of individuals and populations through the advancement of systematic methods to address decision-making under conditions of uncertainty, and to provide a training ground for scholars in the field of medical decision making. Members include researchers, clinicians, educators, managers and policy makers from varied backgrounds and academic disciplines. SMDM provides opportunities for collaboration, networking and mentorship to professionals and trainees…
Preferences/Values | Cost-Effectiveness Analysis | Costing Methods | Value of Information | Global | Priority Setting/Ethics | Decision Analysis | Health/Medicine | North America | Europe -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Preferences/Values | Cost-Effectiveness Analysis | Costing Methods | Value of Information | Global | Priority Setting/Ethics | Health Outcomes | Mathematical Models | Technology Assessment | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Evidence Synthesis | Cost-Effectiveness Analysis | Costing Methods | Global | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine -
OrganizationWeb Portal 2024Global Health Cost Consortium
The Global Health Cost Consortium (GHCC) is a new three-year initiative funded by the Bill …
The Global Health Cost Consortium (GHCC) is a new three-year initiative funded by the Bill and Melinda Gates Foundation to provide decision-makers with improved resources to estimate the costs of HIV and tuberculosis (TB) programs. GHCC’s goal is to increase the efficiency and effectiveness of HIV and TB prevention and treatment, and drive greater value for money of investments to tackle HIV and TB in low and middle-income countries, by improving the availability, quality, timing, and…
Evidence Synthesis | Cost-Effectiveness Analysis | Costing Methods | Global | Benefit-Cost Analysis | Infectious Diseases | Health Systems | Health/Medicine -
ArticlePublication 2023Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on CEAs
This study developed and applied methods to estimate unrelated future medical costs (UFMC) for women …
This study developed and applied methods to estimate unrelated future medical costs (UFMC) for women with breast cancer in Israel and evaluated the impact of including UFMC in cost-effectiveness analyses (CEAs). Methods included a retrospective cohort study using 14 years of patient-level claims data from breast cancer patients and matched controls. UFMC were estimated through (a) the annual average all-cause healthcare costs of control subjects, and (b) predicted values from a generalized linear model (GLM)…
Cost-Effectiveness Analysis | Costing Methods | Middle East & North Africa | Health/Medicine -
ArticlePublication 2010Alternative Strategies to Reduce Maternal Mortality in India: A Cost-Effectiveness Analysis
This article, published in PLoS Medicine, conducted a cost-effectiveness analysis of strategies to improve pregnancy …
This article, published in PLoS Medicine, conducted a cost-effectiveness analysis of strategies to improve pregnancy and childbirth safety in India. Country- and region-specific data were synthesized using a computer-based model that simulates the natural history of pregnancy and pregnancy-associated complications in individual women, and considers delivery location, attendant, and facility level. Model validation compared projected maternal indicators with empiric data. Strategies consisted of improving coverage of effective interventions that could be provided individually or packaged…
Evidence Synthesis | Cost-Effectiveness Analysis | Global | Mathematical Models | Microsimulation | Maternal/Reproductive Health | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Cost-Effectiveness Analysis | Global | Priority Setting/Ethics | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2019Systematic Review of Economic Evaluations of Vaccination Strategies Against Tuberculosis
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited …
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited and varies by age, so a valid cost-effectiveness study is needed to assist decision-makers in the implementation of cost-effective strategies for BCG vaccination. Using the Quality of Health Economic Studies (QHES) instrument, the authors assessed the quality of published studies involving economic evaluations of BCG vaccination strategies in a variety of regions, target populations, and vaccine types. Most of the…
Evidence Synthesis | Cost-Effectiveness Analysis | Global | Mathematical Models | Infectious Diseases | Health/Medicine -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Cost-Effectiveness Analysis | Global | Policy/Regulation | Health/Medicine